# Pharmacy and Therapeutics Committee

**October 16, 2019 12:00pm -5:00 pm**  
Gold Room, 3rd Floor - 701 E. Jefferson Phoenix, AZ  85034

**Teleconference: 530-500-4054 Passcode: 434924#**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| **12:00 PM** | Welcome and Introductions: Sara Salek, MD, Chief Medical Officer, AHCCCS  
\* May 23, 2019 - P&T Minutes Review and Vote |
| **12:15 PM** | Conflict of Interest Training: Robert L. Ellman, Ellman Law Group LLC                     |
| **12:45 PM** | Non-Supplemental Rebate Class Review: Clinical review by Hind Douiki, PharmD, Magellan    |

1. Antifungal – Oral Agents  
   a. Public Testimony: None

2. Antifungal – Topicals  
   a. Public Testimony: None

3. Antimigraine Agents - Triptans  
   a. Public Testimony: None

4. Beta Blockers  
   a. Public Testimony: None

5. BPH Treatments  
   a. Public Testimony: None

6. Calcium Channel Blockers  
   a. Public Testimony: None

7. Leukotriene Modifiers  
   a. Public Testimony: None

8. Phosphate Binders  
   a. Public Testimony: None

9. Sedative Hypnotics  
   a. Public Testimony: None

10. Topical Steroids- Low, Medium, High & Very High Potency  
    a. Public Testimony: None
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
</table>
| 2:30 PM | **New Drug Reviews:** Hind Douiki, PharmD – Magellan | - Mayzent – Siponimod  
- Rocklatan – Netarsudil and Latanoprost  
- Mavenclad – Cladribine  
- Evenity – Romosozumab-aqqg  
- Diacomit – Stiripentol  
- Skyrizi – Risankizumab  
- Cutaquig – Immune Globulin  
- Egaten – Triclabendazole  
- Sunosi – Solriamfetol  
- Rinvoq – Upadacitinib  
- Vyndamax – Tafamidis |
| 3:00 PM | **Break & Executive Session** |                                                                                       |
| 4:00 PM | **Public Therapeutic Class Votes** |                                                                                       |
| 4:30 PM | **Biosimilar Update:**         |  
- **Herceptin**  
  - Herzuma (trastuzumab-pkrb): FDA approved December 2018; anticipated availability is currently unknown  
  - Ogivri (trastuzumab-dkst): FDA approved December 2017; anticipated availability is currently unknown  
  - Ontruzant (trastuzumab-dttb): FDA approved January 2019; availability anticipated in June 2019  
  - Trazimera (trastuzumab-qyy): FDA approved March 2019; anticipated availability is currently unknown  
  - Kanjinti (Trastuzumab-Anns): available  
- **Avastin**  
  - Zirabev (bevacizumab-bvzr): FDA approved June 2019; anticipated availability is currently unknown  
  - Mvasi (Bevacizumab-awwb): available |
| 5:00 PM | **Meeting Adjournment**        |                                                                                       |
|        | **Meeting Dates:**             | January 22, 2020 & May 19, 2020                                                   |